Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon for Postprandial Hypoglycaemia in RYGB Patients
NCT04836273Phase 2Completed
- Start
- Aug 2021
- Primary completion
- May 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of dasiglucagon in postprandial hypoglycemia. Started Aug 2021; status: completed.
02
Drugs
dasiglucagon
03
Conditions
postprandial hypoglycemia
Beyond the preview
Go deeper on NCT04836273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04836273.